<p>Donanemab has already received a 'breakthrough therapy' designation from the FDA</p>
<p>Several experts have said the available evidence about Aduhelm raises significant doubts about its effectiveness</p>
<p>Agency says it has granted approval on the condition that drug maker Biogen conduct a new clinical trial</p>